From CNBC: 2025-04-16 13:30:00

Abbott Laboratories’ stock surged after reporting a strong first-quarter performance. Revenue reached $10.36 billion, with organic sales rising 8.3%. Adjusted earnings per share increased to $1.09. Despite a slight revenue miss, Abbott reaffirmed its 2025 earnings guidance of $5.05 to $5.25 per share. The company is optimistic despite tariff challenges. Shares of Abbott have outperformed the market this year due to strong growth in its medical technology business. The company is focused on expanding its growth in other geographies to offset challenges in China. Abbott’s continuous glucose monitors and other medical devices have shown strong sales growth, providing momentum for future earnings. Despite some setbacks, Abbott’s outlook remains positive, and the company is actively working to mitigate any tariff impacts it may face. Abbott’s performance in the first quarter demonstrated strong growth in its key business segments, offsetting any concerns about tariffs or litigation. The company’s focus on innovation and expanding its product offerings positions Abbott for continued success in the medical technology industry.



Read more at CNBC:: Abbott Labs shares surge on earnings and a big sign of confidence in the business